HealthDay - Immune-Based Drug Shows Promise Against Advanced Melanoma

 – June 1, 2013  –– 

Nearly one-third of patients with advanced melanomas who received nivolumab, a new immune-based drug, experienced reductions in the size of their tumors, according to a preliminary study scheduled for presentation scheduled Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago. "The results of this study are truly remarkable and demonstrate that immunotherapy truly can make the difference for many melanoma patients," said Dr. Yvonne Saenger, assistant professor of hematology/oncology and dermatology at the Icahn School of Medicine at Mount Sinai.

- Dr. Yvonne Saenger, Assistant Professor, Medicine, Hematology and Medical Oncology, The Mount Sinai Medical Center

Learn more